Bookmarks
Clarity IBD
Safe People
Royal Devon and Exeter NHS Foundation Trust
CQC Registered Health or/and Social Care provider
Tariq Ahmad
Safe Projects
eDRIS-2021-0234
The CLARITY trial is looking at the impact of two biologic medicines (infliximab and vedolizumab) on COVID-19 infection, vaccination and immune response in people with Crohn’s or Colitis. The study also takes into account other medicines that people may be taking alongside their infliximab or vedolizumab, for example azathioprine or methotrexate. The researchers want to see if people on these medicines produce the same immune response to coronavirus and to coronavirus vaccines. CLARITY is a one year study led by the IBD research team at the Royal Devon and Exeter NHS Foundation Trust and the University of Exeter Medical School. The study involves 6,935 patients from 92 UK hospitals. Crohn’s & Colitis UK are supporting this research. Researchers are using blood samples collected since the start of 2020 to look at differences in positive antibody rates between people with Crohn’s or Colitis on different drugs, and then look at what happens people have the first and second doses of their coronavirus vaccines.
11/02/2021
Safe Data
COVID19 test
SICSAG (Scottish Intensive Care Society Audit Group)
COVID19 Vaccination
General Acute Inpatient and Day Case - Scottish Morbidity Record (SMR01)
National Records of Scotland (NRS) - Deaths Data
Safe Setting
Release